Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.GMTX · Entity 2273 | CFO | May 31, 2022 | June 02, 2022 |
| Elicio Therapeutics, Inc.ELTX · Entity 299 | Chief Financial Officer | February 01, 2024 | February 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date May 31, 2022 · Filed June 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,615 |
Reported balance
After 2022-05-31 transaction · row 1
1 source rowRow 1 · 2022-05-31 · Grant · Acquired 9,960 · Balance 17,615 F1: These shares were acquired under the Gemini Therapeutics, Inc. 2021 Employee Stock Purchase Plan ("ESPP"). F2: In accordance with the terms of the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Gemini Therapeutics, Inc. 2021 Employee Stock Purchase Plan ("ESPP").
F2: In accordance with the terms of the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022.
Elicio Therapeutics, Inc.
Report date February 01, 2024 · Filed February 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2034-02-01 | Direct | 43,225 |
Reported balance
After 2024-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-01 · Grant · Acquired 43,225 · Balance 43,225 F1: Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMAG PHARMACEUTICALS, INC.
Report date November 16, 2020 · Filed November 17, 2020
Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 31,538 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 9,500 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
KalVista Pharmaceuticals, Inc.
Report date June 11, 2026 · Filed June 11, 2026
Section 16 reporting ended · disclosed 2026-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Disposition to issuer · Disposed 21,661 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.87 · Expires 2034-09-08 | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Disposition to issuer · Disposed 55,000 · Balance 0 F4: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F6: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time. F5: 3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Disposition to issuer · Disposed 93,750 · Balance 0 F4: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F6: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time. F7: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger").
F2: The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.
F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof.
F4: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F5: 3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate
F6: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time.
F7: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 11, 2026 20:25 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerRestricted Stock Unit · Derivative | 93,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001815308-26-000006 · form4-06112026_080631.xml · derivative · entry 4 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,750 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F6 · price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time. F7 · derivative.exercise_date: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date. F7 · derivative.expiration_date: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date. Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 20:25 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerRestricted Stock Unit · Derivative | 55,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001815308-26-000006 · form4-06112026_080631.xml · derivative · entry 3 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F6 · price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time. F5 · derivative.exercise_date: 3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate F5 · derivative.expiration_date: 3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 20:25 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $11.87 | Not disclosed |
DisclosureSEC source: 0001815308-26-000006 · form4-06112026_080631.xml · derivative · entry 2 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2034-09-08 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 20:25 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerCommon Stock | 21,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001815308-26-000006 · form4-06112026_080631.xml · nonDerivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). Read SEC document |
| May 22, 2026 Filed May 26, 2026 23:32 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 1,489 | $26.78 | $39,881.97 |
DisclosureSEC source: 0001815308-26-000004 · form4-05262026_110551.xml · nonDerivative · entry 2 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,661 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:32 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Exercise / conversionRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001815308-26-000004 · form4-05262026_110551.xml · derivative · entry 3 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate. F3 · derivative.expiration_date: 3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:32 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001815308-26-000004 · form4-05262026_110551.xml · nonDerivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| April 17, 2026 Filed Apr 20, 2026 23:40 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 1,862 | $20.22 | $37,642.75 |
DisclosureSEC source: 0001815308-26-000003 · form4-04202026_110449.xml · nonDerivative · entry 2 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,150 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 23:40 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Exercise / conversionRestricted Stock Unit · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001815308-26-000003 · form4-04202026_110449.xml · derivative · entry 3 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date. F3 · derivative.expiration_date: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 23:40 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001815308-26-000003 · form4-04202026_110449.xml · nonDerivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 00:42 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 1,767 | $15.57 | $27,506.54 |
DisclosureSEC source: 0001815308-26-000002 · form4-02252026_120203.xml · nonDerivative · entry 2 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,762 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.5253 to $15.56698 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2026 Filed Feb 25, 2026 00:42 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Exercise / conversionRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001815308-26-000002 · form4-02252026_120203.xml · derivative · entry 3 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate. F4 · derivative.expiration_date: 3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate. Read SEC document |
| February 21, 2026 Filed Feb 25, 2026 00:42 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001815308-26-000002 · form4-02252026_120203.xml · nonDerivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:10 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001815308-26-000001 · form4-01212026_090135.xml · derivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate. F2 · derivative.expiration_date: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 23:50 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 4,471 | $13.45 | $60,139.42 |
DisclosureSEC source: 0001815308-25-000004 · form4-11262025_111126.xml · nonDerivative · entry 2 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,529 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| November 21, 2025 Filed Nov 26, 2025 23:50 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001815308-25-000004 · form4-11262025_111126.xml · derivative · entry 3 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 3/16th of the total number of shares underlying the RSUs vested on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate. F3 · derivative.expiration_date: 3/16th of the total number of shares underlying the RSUs vested on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate. Read SEC document |
| November 21, 2025 Filed Nov 26, 2025 23:50 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001815308-25-000004 · form4-11262025_111126.xml · nonDerivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 01:35 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantRestricted Stock Unit · Derivative | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005611 · form4-02262025_010210.xml · derivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate. F2 · derivative.expiration_date: 3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:34 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.87 | $0.00 |
DisclosureSEC source: 0001415889-24-023216 · form4-09112024_080900.xml · derivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_date: The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. F1 · derivative.expiration_date: The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 11:01 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (right to buy) · Derivative | 43,225 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001140361-24-005499 · form4.xml · derivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,225 Underlying: Common Stock · 43,225 shares Expires 2034-02-01 F1 · derivative.exercise_date: Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 21:25 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (right to buy) · Derivative | 75,484 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001140361-23-028420 · form4.xml · derivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,484 Underlying: Common Stock · 75,484 shares Expires 2033-06-01 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on May 15, 2024 with the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to the Reporting Person continuing to provide services to the Issuer through the applicable vesting dates, and provided that in the event there is a change in control of the Issuer, followed by a subsequent termination of the Reporting Person's employment without cause (or a material diminishment of his role) within 12 months of the change of control, any unvested options granted will immediately vest. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 23:14 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantCommon Stock | 9,960 | $1.09 | $10,856.40 |
DisclosureSEC source: 0001209191-22-033719 · doc4.xml · nonDerivative · entry 1 Piekos Brian · CIK 0001815308 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,615 F1 · kind: These shares were acquired under the Gemini Therapeutics, Inc. 2021 Employee Stock Purchase Plan ("ESPP"). F2 · price: In accordance with the terms of the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 14:01 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantRestricted Stock Units · Derivative | 280,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003268 · doc4.xml · derivative · entry 1 Piekos Brian · CIK 0001815308 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,876 Underlying: Common Stock · 280,876 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock. F2 · derivative.exercise_date: These Restricted Stock Units shall vest on the one (1)-year anniversary of the date of grant. F2 · derivative.expiration_date: These Restricted Stock Units shall vest on the one (1)-year anniversary of the date of grant. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 21:49 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantRestricted Stock Units · Derivative | 90,720 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-040808 · doc4.xml · derivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,720 Underlying: Common Stock · 90,720 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock. F2 · derivative.exercise_date: Thirty-three percent (33%) of the Restricted Stock Units shall vest upon the achievement of a clinical milestone, and the remaining sixty-seven percent (67%) of the Restricted Stock Units shall vest on the one (1)-year anniversary of the achievement of this clinical milestone. F2 · derivative.expiration_date: Thirty-three percent (33%) of the Restricted Stock Units shall vest upon the achievement of a clinical milestone, and the remaining sixty-seven percent (67%) of the Restricted Stock Units shall vest on the one (1)-year anniversary of the achievement of this clinical milestone. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:45 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | PurchaseCommon Stock | 7,655 | $9.46 | $72,431.61 |
DisclosureSEC source: 0000899243-21-019763 · doc4.xml · nonDerivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,655 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.30 to $9.50. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 20:06 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 377,734 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001213900-21-021524 · ownership.xml · derivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,734 Underlying: Common Stock · 377,734 shares Expires 2031-04-11 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, April 12, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:42 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126319 · a4.xml · derivative · entry 2 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,500 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:42 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerCommon Stock | 31,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126319 · a4.xml · nonDerivative · entry 1 Piekos Brian · CIK 0001815308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.